Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published January 2012
  • Article
  • Info & Metrics
  • PDF
Loading

GRK Expression in Glioblastoma

Woerner et al. Page 156

The role of G-protein coupled–receptors (GPCR) in cancer and how to best target their function remains incompletely understood. Using The Cancer Genome Atlas, primary tumor specimens, and in vitro studies, Woerner and coworkers found that expression of G-protein coupled–receptor kinases (GRK), critical regulators of GPCR function, is altered in glioblastoma in a molecular subtype–specific fashion. Decreased GRK3 expression in classical glioblastoma was associated with a growth advantage, which was blocked by reconstitution of GRK3 expression. These data indicate that GPCRs function to regulate glioblastoma growth and suggest that modulation of GPCR phosphorylation may be an important therapeutic strategy.

Loss of EcSOD Promotes Lung Cancer Progression

Teoh-Fitzgerald et al. Page 40

The antioxidant enzyme extracellular superoxide dismutase EcSOD is downregulated in a large proportion of human lung cancers. To explore its role in cancer, Teoh-Fitzgerald and colleagues examined EcSOD gene expression, as well as the biological effects of its reexpression in EcSOD-negative tumor cells. Epigenetic silencing by aberrant cytosine methylation of the promoter was the most frequent cause of expression loss in human lung adenocarcinoma compared with normal lung. Reexpression of EcSOD inhibited the in vitro invasiveness of human lung adenocarcinoma cells. This study identifies EcSOD as an epigenetically regulated lung cancer target and a modifier of the malignant phenotype.

WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis

Garimella et al. Page 75

TRAIL induces apoptosis in basal/triplenegative breast cancer (TNBC) cell lines, whereas other subtypes are relatively resistant. Inhibition of WEE1, a cell-cycle checkpoint regulator, causes increased cell death in cancer cell lines. Here, Garimella and colleagues show that pretreatment with WEE1 inhibitor increased the toxicity of TRAIL in TNBC cell lines. This effect is attributed to increased surface expression of death receptors resulting in increased caspase activation initiated by caspase-8. These data suggest that the combination of WEE1 inhibitor and TRAIL could provide a novel approach to targeted therapy for TNBC.

Elevated Alternative Nonhomologous End Joining in Breast Cancers

Tobin et al. Page 96

Although largely unknown, the abnormalities in DNA repair that underlie the genomic instability in sporadic cancers are potential therapeutic targets. Tobin and colleagues have characterized a novel defect in DNA double-strand break repair in hormone therapy–resistant breast cancer that can be identified in breast cancer cell lines and tumor biopsies and can be selectively targeted by a combination of PARP and DNA ligase inhibitors. These preclinical studies provide the rationale for the development of effective therapeutic strategies for hormone therapy–resistant breast cancer that may be applicable to other cancers, including leukemias, with similar DNA repair abnormalities.

  • ©2011 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Research: 10 (1)
January 2012
Volume 10, Issue 1
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Res January 1 2012 (10) (1) 1;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Res January 1 2012 (10) (1) 1;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • GRK Expression in Glioblastoma
    • Loss of EcSOD Promotes Lung Cancer Progression
    • WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis
    • Elevated Alternative Nonhomologous End Joining in Breast Cancers
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement